Mauritz Kop Fellow at Inter-CeBIL Harvard Cambridge Copenhagen

Harvard-Cambridge-Copenhagen, Sept 15, 2023 — Mauritz Kop has accepted a position as an Inter-CeBIL Fellow at the prestigious Novo Nordisk Foundation Copenhagen-Cambridge-Harvard Inter-CeBIL Programme for International Collaborative Bioscience Innovation & Law. In this role, Kop will focus his research on Advanced Medical Computing, Artificial Intelligence (AI) and Quantum Technologies within the life sciences ecosystem.

About the Inter-CeBIL Programme

The Inter-CeBIL Programme is a world-leading research hub dedicated to identifying and tackling the most significant legal and regulatory barriers to health and life science innovation. The initiative fosters robust knowledge networks to provide tailored legal and regulatory support to patients, researchers, businesses, and incubators, with the ultimate goal of ensuring that health and life science innovations can safely and effectively reach patients and markets.

This international collaboration brings together top-tier academic institutions to drive progress in healthcare and biotechnology. The program is a joint effort between the Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) at the University of Copenhagen, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, and the University of Cambridge, among other key partners. The program is led by a distinguished team, including Professor Timo Minssen as the Founding Director of CeBIL at the University of Copenhagen, Professor I. Glenn Cohen who leads Harvard Law School’s contribution, and Professor Mateo Aboy who leads the Cambridge part.

Mauritz Kop has accepted a position as an Inter-CeBIL Fellow at the prestigious Novo Nordisk Foundation Copenhagen-Cambridge-Harvard Inter-CeBIL Programme for International Collaborative Bioscience Innovation & Law.

Key Research Areas

The Inter-CeBIL Programme centers its research on three key "grand challenges":

1. Advanced Medical Computing: Focusing on Artificial Intelligence (AI) and Quantum Technologies (QT).

2. Pandemic Preparedness & Anti-Microbial Resistance (AMR).

3. Sustainable Innovation & Biosolutions: Encompassing eco-systems, drug R&D, drug regulation, and data infrastructures.

Focus on Key Area 1: Advanced Medical Computing, AI & Quantum Technology

This key research area addresses the increasingly critical role of advanced computing in the life sciences and medical sectors. Algorithms are becoming fundamental building blocks in a wide range of medical devices, digital health technologies (DHTs), and drug discovery tools (DDTs). The use of advanced computing, including AI/ML and quantum computing (QC), holds immense potential benefits for the life sciences, drug discovery, and medical sectors. These advancements also raise significant legal, ethical, governance, and regulatory issues that the program aims to address.

In his capacity as an Inter-CeBIL Fellow, Mauritz Kop will contribute his deep expertise in quantum-AI, its governance, and its legal-ethical implications to this key research area, helping to navigate the complex challenges and opportunities presented by these cutting-edge technologies.

A Network of Distinguished Fellows

Mr. Kop joins a cohort of distinguished Inter-CeBIL research fellows from top universities around the globe. This network includes prominent scholars such as Professor Urs Gasser of the Technical University of Munich, who is - like Prof. Mateo Aboy from Cambridge- also a Fellow at the Stanford Center for Responsible Quantum Technology, fostering further synergy between these leading research initiatives. This collaborative and interdisciplinary environment is essential for developing comprehensive and practically relevant solutions to the challenges facing bioscience innovation.

The Inter-CeBIL Programme continues to shape global understanding in these critical areas, with a mission to translate groundbreaking research into tangible health impacts for patients worldwide.

Our Sponsor: The Novo Nordisk Foundation

This research was made possible through the generous support of the Novo Nordisk Foundation via a grant for the scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL).

The Novo Nordisk Foundation is an independent Danish enterprise foundation with a vision to improve people's health and the sustainability of society and the planet. Its mission is to advance knowledge and solutions to support societal goals by funding scientific research, innovation, and education. The Foundation provides a stable basis for the commercial and research activities of the Novo Group companies and supports scientific, humanitarian, and social causes.

A key focus for the Foundation is fostering a world-class life science ecosystem, recognizing it as a prerequisite for scientific breakthroughs and the development of new technologies that can solve major societal challenges. This includes supporting research and innovation within health, sustainability, and the natural sciences through grants awarded in open competition and for standalone initiatives.

The grant supporting the Inter-CeBIL programme (Grant No. NNF23SA0087056) exemplifies the Foundation's commitment to tackling the legal and regulatory barriers that can impede health and life science innovation. This initiative aims to translate groundbreaking biomedical research into safe, effective, and accessible therapies by analyzing and addressing the most significant legal challenges. The Foundation's support enables a global, interdisciplinary collaboration between leading research institutions to develop actionable insights and practical tools that benefit patients, researchers, and the broader healthcare innovation ecosystem.

For more information about the Inter-CeBIL programme, see https://jura.ku.dk/cebil/research/inter-cebil/

The University of Copenhagen’s Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and the Novo Nordisk Foundation Inter-CeBIL Program proudly support the 2nd Annual Stanford Responsible Quantum Technology Conference hosted by the Stanford Center for Responsible Quantum Technology.